Coherus BioSciences CHRS announced that UDENYCA preliminary unaudited net sales for the second quarter expected in the range of $79 million-$84 million.
Coherus BioSciences shares were trading lower by 13% at $19.77 on Monday morning. The stock has a 52-week high of $23.43 and a 52-week low of $8.32.
Related Links:
Fast Track Designation By FDA Granted For Prevail's Parkinson's Treatment
Sol-Gel Technologies Shares Positive Results For Skin Breakout Cream
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
